JP4572276B2 - Ｔ細胞調節遺伝子およびその使用方法 - Google Patents

Ｔ細胞調節遺伝子およびその使用方法 Download PDF

Info

Publication number
JP4572276B2
JP4572276B2 JP2003509084A JP2003509084A JP4572276B2 JP 4572276 B2 JP4572276 B2 JP 4572276B2 JP 2003509084 A JP2003509084 A JP 2003509084A JP 2003509084 A JP2003509084 A JP 2003509084A JP 4572276 B2 JP4572276 B2 JP 4572276B2
Authority
JP
Japan
Prior art keywords
tim
polymorphism
seq
cells
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003509084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500039A5 (https=
JP2005500039A (ja
Inventor
ジェニファー ジョーンズ マクインタイア，
ローズマリー エイチ． デクルイフ，
デール ティー． ウメツ，
ゴードン ジェイ． フリーマン，
ヴィジェイ ククロー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2005500039A publication Critical patent/JP2005500039A/ja
Publication of JP2005500039A5 publication Critical patent/JP2005500039A5/ja
Application granted granted Critical
Publication of JP4572276B2 publication Critical patent/JP4572276B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2003509084A 2001-06-29 2002-07-01 Ｔ細胞調節遺伝子およびその使用方法 Expired - Fee Related JP4572276B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30234401P 2001-06-29 2001-06-29
PCT/US2002/020890 WO2003002722A2 (en) 2001-06-29 2002-07-01 T cell regulatory genes and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2006211500A Division JP4351233B2 (ja) 2001-06-29 2006-08-02 Ｔ細胞調節遺伝子およびその使用方法
JP2009239582A Division JP2010057492A (ja) 2001-06-29 2009-10-16 Ｔ細胞調節遺伝子およびその使用方法

Publications (3)

Publication Number Publication Date
JP2005500039A JP2005500039A (ja) 2005-01-06
JP2005500039A5 JP2005500039A5 (https=) 2006-09-21
JP4572276B2 true JP4572276B2 (ja) 2010-11-04

Family

ID=23167357

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003509084A Expired - Fee Related JP4572276B2 (ja) 2001-06-29 2002-07-01 Ｔ細胞調節遺伝子およびその使用方法
JP2006211500A Expired - Fee Related JP4351233B2 (ja) 2001-06-29 2006-08-02 Ｔ細胞調節遺伝子およびその使用方法
JP2009239582A Withdrawn JP2010057492A (ja) 2001-06-29 2009-10-16 Ｔ細胞調節遺伝子およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006211500A Expired - Fee Related JP4351233B2 (ja) 2001-06-29 2006-08-02 Ｔ細胞調節遺伝子およびその使用方法
JP2009239582A Withdrawn JP2010057492A (ja) 2001-06-29 2009-10-16 Ｔ細胞調節遺伝子およびその使用方法

Country Status (11)

Country Link
US (2) US7553939B2 (https=)
EP (1) EP1406653A4 (https=)
JP (3) JP4572276B2 (https=)
KR (1) KR20040014997A (https=)
CN (1) CN1538853A (https=)
CA (1) CA2452196A1 (https=)
IL (1) IL159627A0 (https=)
MX (1) MXPA04000034A (https=)
NZ (1) NZ530451A (https=)
WO (1) WO2003002722A2 (https=)
ZA (1) ZA200400013B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
EP1401869B1 (en) * 2001-06-01 2007-12-26 Biogen Idec MA Inc. Molecules and methods for inhibiting shedding of kim-1
EP1406653A4 (en) * 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
AU2003303082B2 (en) * 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DK1585546T3 (da) * 2002-12-30 2008-12-08 Biogen Idec Inc KIM- 1- Antagonister og Brug til at Modulere Immunsystem
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
DK1613750T3 (en) * 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
MXPA06003686A (es) * 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
AU2005231685A1 (en) * 2004-03-24 2005-10-20 Telos Pharmaceuticals Llc Compositions as adjuvants to improve immune responses to vaccines and methods of use
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
CN1778816B (zh) * 2004-11-22 2010-07-07 中国人民解放军第二军医大学 人细胞表面膜分子及用途
EP2251037B1 (en) 2005-03-02 2015-01-14 Biogen Idec MA Inc. KIM-1 antibodies for treatment of TH1/TH2-mediated conditions
KR100746312B1 (ko) * 2005-03-14 2007-08-03 한국화학연구원 수용성 산화철 나노 입자 및 이의 제조방법
WO2008036765A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
EP2268832A2 (en) * 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2010095461A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
JP6196034B2 (ja) * 2012-12-20 2017-09-13 ライオン株式会社 高血糖リスク判定用マーカーペプチドおよびその用途
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
TWI726920B (zh) * 2015-10-14 2021-05-11 耶魯大學 基因體規模的ｔ細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Immunomodulatory proteins ICOS ligand variants and uses thereof
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
US11203637B2 (en) * 2016-08-26 2021-12-21 Beigene, Ltd. Anti-Tim-3 antibodies and use thereof
EP4089116A1 (en) 2016-09-27 2022-11-16 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
WO2018086594A1 (en) 2016-11-11 2018-05-17 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tim-3
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
EP3688032B1 (en) 2017-09-26 2025-11-05 Cero Therapeutics Holdings, Inc. Chimeric engulfment receptor molecules and methods of use
CN108037292A (zh) * 2017-11-29 2018-05-15 天津市湖滨盘古基因科学发展有限公司 一种人的磷脂酰丝氨酸受体突变蛋白及其应用
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
CN110412263B (zh) * 2019-07-31 2023-01-31 中国农业科学院茶叶研究所 一种快速高效的茶树质体型谷氨酰胺合成酶基因定位方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
CA2319129A1 (en) * 1998-01-30 1999-08-05 Human Genome Sciences, Inc. 67 human secreted proteins
CA2324648C (en) * 1998-03-27 2013-02-26 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
WO2002081517A2 (en) * 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
EP1406653A4 (en) * 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
MXPA04000034A (es) 2005-11-23
JP2007000146A (ja) 2007-01-11
JP2010057492A (ja) 2010-03-18
JP4351233B2 (ja) 2009-10-28
JP2005500039A (ja) 2005-01-06
EP1406653A2 (en) 2004-04-14
CN1538853A (zh) 2004-10-20
CA2452196A1 (en) 2003-01-09
US20090252737A1 (en) 2009-10-08
KR20040014997A (ko) 2004-02-18
IL159627A0 (en) 2004-06-01
WO2003002722A3 (en) 2003-04-03
EP1406653A4 (en) 2005-05-04
WO2003002722A2 (en) 2003-01-09
NZ530451A (en) 2008-04-30
WO2003002722A9 (en) 2004-04-15
US20030124114A1 (en) 2003-07-03
US7553939B2 (en) 2009-06-30
ZA200400013B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
JP4572276B2 (ja) Ｔ細胞調節遺伝子およびその使用方法
US9683049B2 (en) Modulation of TIM receptor activity in combination with cytoreductive therapy
US7838220B2 (en) T cell regulatory genes associated with immune disease
US8288096B2 (en) Diagnostic method for epilepsy
US20060089306A1 (en) New epilepsy mutations
CA2314677A1 (en) Asthma related genes
EP1401497B1 (en) Methods for the modulation of il-13
JP2001517682A (ja) 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
JPWO2003031620A1 (ja) 新規クラスｉｉサイトカイン受容体
JP2000509255A (ja) 感覚神経障害と関連した遺伝子ファミリー
US7709225B2 (en) Nucleic acids encoding mutations in sodium channels related to epilepsy
US20040203144A1 (en) Methods and compositions for treating respiratory mucin production associated disease conditions
AU2002318462A1 (en) T cell regulatory genes and methods of use thereof
AU2004200978A1 (en) A diagnostic method for epilepsy
Mostecki et al. A SOCS-1 Promoter Variant Is Associated
WO2002046389A2 (en) Genes associated with allergic hypersensitivity and mast cell activation
US20030224423A1 (en) Method of testing for allergic diseases
HK1069996A (en) T cell regulatory genes and methods of use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050630

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060704

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080425

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090323

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091016

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100615

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100715

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130827

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees